Webinar
November 25, 2025 | 4pm CET
Unveiling Devyser CFTR IVDR: Future-proof your cystic fibrosis diagnostics
Join us for the launch webinar of our newly CE-marked (IVDR) assay, Devyser CFTR. This NGS test is suitable to support cystic fibrosis diagnostic testing and for screening newborns and carriers. We will walk through the single-tube lab workflow, the assay design, and how our accompanying analysis software, Amplicon Suite, presents results clearly and practically. The session is intended for laboratory professionals, as well as clinicians, who want a straightforward overview of the assay, from run planning to data review and results.
Why attend this webinar?
Why attend this webinar?
- See how an unmatched single-tube workflow requiring less than 45 minutes hands-on time simplifies setup, batching, and saves resources.
- Learn how SNVs/indels, CNVs, and poly-T/TG are consolidated in one run, and how our unique dual detection approach ensures robust analysis of exon-spanning deletions.
- Preview the analysis software Amplicon Suite, which reduces bioinformatics burden with a clear, user-friendly readout.
- Discover how the assay can flexibly support diagnosis, carrier screening, and newborn screening.
We look forward to your participation.
Don’t miss the chance to engage directly with our speaker and get your questions answered during the live Q&A.
Devyser products are distributed worldwide. Not all intended uses and applications mentioned here are available in every country. Please consult your local sales representative for details.
Don’t miss the chance to engage directly with our speaker and get your questions answered during the live Q&A.
Devyser products are distributed worldwide. Not all intended uses and applications mentioned here are available in every country. Please consult your local sales representative for details.
Latest from the Devyser blog
View all
Devyser launches a new updated NGS assay to simplify thalassemia testing
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed...
Read More
Devyser Thalassemia achieves 99.9% sensitivity: Insights from a recent study
Thalassemia and hemoglobinopathies are among the most common genetic disorders worldwide, affecting...
Read More